CELA3B: A Promising Drug Target and Biomarker for Proteasome-Mediated Diseases

Target Name: CELA3B

NCBI ID: G23436

CELA3B

CELA3B: A Promising Drug Target and Biomarker for Proteasome-Mediated Diseases

Introduction

Proteasome-mediated diseases are a class of genetic disorders caused by the misfolding and subsequent aggregation of proteins. These diseases include various neurodegenerative disorders, such as Alzheimer's, Parkinson's, and Huntington's diseases, as well as systemic autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. CELA3B, a proteinase E, has been identified as a potential drug target and biomarker for these diseases. In this article, we will explore the biology of CELA3B and its potential as a drug target and biomarker.

The biology of CELA3B

CELA3B is a 29-kDa protein that is expressed in various tissues, including the brain, muscle, and heart. It is a key component of the proteasome, a complex protein that removes damaged or unnecessary proteins from the cell. In misfolded proteins, CELA3B plays a crucial role in their degradation and subsequent aggregation, contributing to the development of neurodegenerative diseases.

CELA3B functions as a proteinase E, which is a type of enzyme that recognizes and attacks specific amino acid residues within a protein. In CELA3B, the E represents the enzyme's catalytic activity, while the B represents the substrate, which is the target amino acid residue . CELA3B's specificity for its substrate, as well as its ability to cleave specific amino acids, makes it an attractive candidate as a drug target.

CELA3B's role in neurodegenerative diseases

The misfolding and aggregation of proteins is a hallmark feature of neurodegenerative diseases, and CELA3B is involved in this process. Studies have shown that CELA3B levels are elevated in the brains of individuals with neurodegenerative diseases, and that inhibiting CELA3B activity can lead to reduced neurodegeneration. Additionally, CELA3B has been shown to play a role in the development of neurofibrillary tangles, a hallmark of Alzheimer's disease, by promoting the formation of these tangles.

CELA3B's potential as a drug target

The potential of CELA3B as a drug target is due to its unique biology and its ability to interact with specific molecules. One approach to targeting CELA3B is to use small molecules that can inhibit its catalytic activity. This would result in a decrease in the amount of misfolded proteins produced in the brain, which could potentially slow the progression of neurodegenerative diseases.

Another approach to targeting CELA3B is to use antibodies that specifically recognize and target its catalytic active site. This would allow for direct intervention in the regulation of CELA3B activity and potentially lead to the reversal of neurodegeneration.

CELA3B's potential as a biomarker

CELA3B may also serve as a biomarker for neurodegenerative diseases. The aggregation of misfolded proteins is a hallmark feature of these diseases, and CELA3B's ability to promote this aggregation makes it an attractive candidate as a biomarker. Additionally, the levels of CELA3B in the brain may be a useful indicator of the severity of neurodegeneration in individuals with neurodegenerative diseases.

Conclusion

In conclusion, CELA3B is a proteinase E that is involved in the regulation of protein folding and aggregation. Its role in the development and progression of neurodegenerative diseases makes it an attractive candidate as a drug target and biomarker. Further research is needed to fully understand the biology of CELA3B and its potential as a drug

Protein Name: Chymotrypsin Like Elastase 3B

Functions: Efficient protease with alanine specificity but only little elastolytic activity

The "CELA3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CELA3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets